Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918

This article has now been updated. Please use the final version.

The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment: A Case Report
Goki SudaMasato NakaiTakuya ShoMegumi KimuraTomoe ShimazakiOsamu MaeharaTaku ShigesawaKazuharu SuzukiAkihisa NakamuraMasatsugu Oharal Machiko UmemuraNaoki KawagishiMasaru BabaMitsuteru NatsuizakaKenichi MorikawaKoji OgawaNaoya Sakamotofor the NORTE Study Group
Author information
JOURNAL OPEN ACCESS Advance online publication

Article ID: 2077-18

Details
Abstract

Clinical trials and real-world data have proven that hepatitis C virus (HCV) in most infected patients can be eradicated by direct-acting antivirals (DAAs). However, the proper retreatment regimen for hemodialysis patients with HCV infection who have previously failed to respond to DAAs has not been clarified. We herein report, for the first time, the successful retreatment with glecaprevir and pibrentasvir, of three hemodialysis patients with genotype 1 or 2 HCV infection, who had previously failed to respond to combination therapy with an HCV-NA5A inhibitor (daclatasvir) and an HCV protease inhibitor (asunaprevir).

Content from these authors
© 2019 by The Japanese Society of Internal Medicine
feedback
Top